Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] logo
Important Safety Information | Patient Site
Prescribing Information
    • Pharmacology
    • Mechanism of Action
    • Prophylaxis
    • On Demand
    • Perioperative
    • Safety Profile
    • Adults & Adolescents
    • Children
    • Reconstitution & Administration
  • Costs & Coverage
    • Patient Education
    • Education for You
    • How to Order
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] logo

Indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. Esperoct® is not indicated for the treatment of von Willebrand disease.

Prescribing Information
Important Safety Information | Patient Site

Kogenate® FS is being discontinued. Click here to review Esperoct® pharmacology.

Kogenate® FS is being discontinued. Click here to review Esperoct® pharmacology.

Patients who take Esperoct® are likely to stay with Esperoct®

Among extended half-life (EHL) products, fewer Esperoct® prescriptions were switched to another product.1,a

aBased on data for Q2 2020-Q2 2021; accounts for net gains and losses of patients switching to and from extended half-life rFVIII available for at least one year.1  

See why

Bradley O. lives with severe hemophilia A and uses Esperoct®

Help your SHL patients consider Esperoct®

Among extended half-life (EHL) products, fewer Esperoct® prescriptions were switched to another product.1,a

SHL=standard half-life.
aBased on data for Q2 2020-Q2 2021; accounts for net gains and losses of patients switching to and from extended half-life rFVIII available for at least one year.1  

 

Compare products

Bradley O. lives with severe hemophilia A and uses Esperoct®

Patients who take Esperoct® are likely to stay with Esperoct®

Among extended half-life (EHL) products, fewer Esperoct® prescriptions were switched to another product.1,a

aBased on data for Q2 2020-Q2 2021; accounts for net gains and losses of patients switching to and from extended half-life rFVIII available for at least one year.1  

See why

Bradley O. lives with severe hemophilia A and uses Esperoct®

Bradley O. lives with severe hemophilia A and uses Esperoct®

Help your SHL patients consider Esperoct®

Among extended half-life (EHL) products, fewer Esperoct® prescriptions were switched to another product.1,a

SHL=standard half-life.
aBased on data for Q2 2020-Q2 2021; accounts for net gains and losses of patients switching to and from extended half-life rFVIII available for at least one year.1  

Compare products

Bradley O. lives with severe hemophilia A and uses Esperoct®

Bradley O. lives with severe hemophilia A and uses Esperoct®

Move beyond the thresholda

Esperoct® is an extended half-life (EHL) rFVIII treatment for your patients with hemophilia A.1

aOf 1% trough levels for standard half-life (SHL) products in adults and adolescents.1,2

Explore Esperoct®
Data icon

Stable trough levels and decreased ABR from long-term prophylaxis

In a post hoc analysis, long-term prophylaxis (≥6 years) showed a stabilization in mean FVIII trough levels and decrease in ABR over time in adults and adolescents taking Esperoct®.3,b

See data

bPost hoc analyses were performed on data from the pathfinder 2 trial of patients aged >12 years with severe hemophilia A. Exploratory descriptive analyses of the data were used to evaluate long-term annual bleed rates and mean factor VIII trough levels which were assessed over time in 61 patients who received ≥6 years of prophylaxis, every 4 days. Limitations of the analyses include the lack of baseline joint status data, which is clinically relevant for phenotypic assessment prior to treatment initiation. The absence limits the ability to draw conclusions regarding improvement in joint status over time. Several trough-level data were excluded if it was believed that they were elevated due to dosing to treat a recent bleed.3

Data icon

Stable trough levels and decreased ABR from long-term prophylaxis

In a post hoc analysis, long-term prophylaxis (≥6 years) showed a stabilization in mean FVIII trough levels and decrease in ABR over time in adults and adolescents taking Esperoct®.3,b

See data

bPost hoc analyses were performed on data from the pathfinder 2 trial of patients aged >12 years with severe hemophilia A. Exploratory descriptive analyses of the data were used to evaluate long-term annual bleed rates and mean factor VIII trough levels which were assessed over time in 61 patients who received ≥6 years of prophylaxis, every 4 days. Limitations of the analyses include the lack of baseline joint status data, which is clinically relevant for phenotypic assessment prior to treatment initiation. The absence limits the ability to draw conclusions regarding improvement in joint status over time. Several trough-level data were excluded if it was believed that they were elevated due to dosing to treat a recent bleed.3

Esperoct® provides your adult and adolescent prophylaxis patients:

Data icon

Stable trough levels and decreased ABR from long-term prophylaxis

In a post hoc analysis, long-term prophylaxis (≥6 years) showed a stabilization in mean FVIII trough levels and decrease in ABR over time in adults and adolescents taking Esperoct®.2,b

See data

bPost hoc analyses were performed on data from the pathfinder 2 trial of patients aged >12 years with severe hemophilia A. Exploratory descriptive analyses of the data were used to evaluate long-term annual bleed rates and mean factor VIII trough levels which were assessed over time in 61 patients who received ≥6 years of prophylaxis, every 4 days. Limitations of the analyses include the lack of baseline joint status data, which is clinically relevant for phenotypic assessment prior to treatment initiation. The absence limits the ability to draw conclusions regarding improvement in joint status over time. Several trough-level data were excluded if it was believed that they were elevated due to dosing to treat a recent bleed.2

Data icon

Stable trough levels and decreased ABR from long-term prophylaxis

In a post hoc analysis, long-term prophylaxis (≥6 years) showed a stabilization in mean FVIII trough levels and decrease in ABR over time in adults and adolescents taking Esperoct®.2,b

See data

bPost hoc analyses were performed on data from the pathfinder 2 trial of patients aged >12 years with severe hemophilia A. Exploratory descriptive analyses of the data were used to evaluate long-term annual bleed rates and mean factor VIII trough levels which were assessed over time in 61 patients who received ≥6 years of prophylaxis, every 4 days. Limitations of the analyses include the lack of baseline joint status data, which is clinically relevant for phenotypic assessment prior to treatment initiation. The absence limits the ability to draw conclusions regarding improvement in joint status over time. Several trough-level data were excluded if it was believed that they were elevated due to dosing to treat a recent bleed.2

Esperoct® provides your adult and adolescent prophylaxis patients:

Low Median ABR

Long-term trial results up to 6.6 years confirm effective
prophylaxis in patients ≥12 years

Bleeding resolution data
See study design

Based on a post hoc analysis, the majority of adults/adolescents who completed the entire trial experienced no annual bleeds after year 1.4,c

View efficacy data

cBased on a post hoc analysis of patients who completed the entire pathfinder 2 trial (n=110) who took Esperoct® 50 IU/kg every 4 days for up to 6.6 years. Patients evaluated at year 2 (n=103), year 3 (n=66), year 4 (n=62), year 5 (n=62), year 6 (n=59).4

High Trough Levels

In a phase 3, open-label study of PTPs >12 years

Trough levels data

for the entire dosing interval1

See study design
Trough levels data

for 90% of the dosing interval1,d

Trough levels data

mean trough levels maintained (N=61) as seen in 6+ years post hoc analysis3,e

Go to pharmacology

dSteady-state FVIII activity profiles were estimated in 143 patients using a one-compartment model with first-order elimination with PK parameters of clearance and volume of distribution.1
e
Exploratory descriptive analyses of the data were used to evaluate long-term annual bleed rates and mean factor VIII trough levels which were assessed over time in 61 patients who received ≥6 years of prophylaxis, every 4 days. Limitations of the analyses include the lack of baseline joint status data, which is clinically relevant for phenotypic assessment prior to treatment initiation. The absence limits the ability to draw conclusions regarding improvement in joint status over time. Several trough-level data were excluded if it was believed that they were elevated due to dosing to treat a recent bleed.3

Vial shown contains 1000 IU.

One Proven Starting Dose

for routine prophylaxis (adults and adolescents)

50 IU/kg
  • No dose adjustment needed and related PK testing required1,5
  • Regimen can be individualized to less or more frequent dosing based on bleeding episodes1
Get the details

Patients who take Esperoct® are likely to stay with Esperoct®

Among EHL products, fewer Esperoct® prescriptions were switched to another product.6,f

ABR=annualized bleed rate; PK=pharmacokinetic; PTP=previously treated patient.

f
Based on data for Q2 2020-Q2 2021; accounts for net gains and losses of patients switching to and from extended half-life rFVIII available for at least one year.6

Low Median ABR

Long-term trial results up to 6.6 years confirm effective
prophylaxis in patients ≥12 years

Bleeding resolution data
See study design

Based on a post hoc analysis, the majority of adults/adolescents who completed the entire trial experienced no annual bleeds after year 1.3,c

View efficacy data

cBased on a post hoc analysis of patients who completed the entire pathfinder 2 trial (n=110) who took Esperoct® 50 IU/kg every 4 days for up to 6.6 years. Patients evaluated at year 2 (n=103), year 3 (n=66), year 4 (n=62), year 5 (n=62), year 6 (n=59).3

High Trough Levels

In a phase 3, open-label study of PTPs >12 years

Trough levels data

for the entire dosing interval4

See study design
Trough levels data

for 90% of the dosing interval4,d

Trough levels data

mean trough levels maintained (N=61) as seen in 6+ years post hoc analysis2,e

Go to pharmacology

dSteady-state FVIII activity profiles were estimated in 143 patients using a one-compartment model with first-order elimination with PK parameters of clearance and volume of distribution.4
e
Exploratory descriptive analyses of the data were used to evaluate long-term annual bleed rates and mean factor VIII trough levels which were assessed over time in 61 patients who received ≥6 years of prophylaxis, every 4 days. Limitations of the analyses include the lack of baseline joint status data, which is clinically relevant for phenotypic assessment prior to treatment initiation. The absence limits the ability to draw conclusions regarding improvement in joint status over time. Several trough-level data were excluded if it was believed that they were elevated due to dosing to treat a recent bleed.2

Vial shown contains 1000 IU.

One Proven Starting Dose

for routine prophylaxis (adults and adolescents)

50 IU/kg
  • No dose adjustment needed and related PK testing required4,5
  • Regimen can be individualized to less or more frequent dosing based on bleeding episodes4
Get the details

ABR=annualized bleed rate; PK=pharmacokinetic; PTP=previously treated patient.

Prescribing Information | Important Safety Information
Esperoct® Overview
(6:23)
Esperoct® Overview
Dr Tami Singleton presents the clinical characteristics of, and her perspective on, extended half-life Esperoct®.
Watch video
Prescribing Information | Important Safety Information

     Please See Prescribing Information

Study design

Giangrande et al (2017 and 2020)
pathfinder 2 phase 3 clinical trial: main phase and extension

Patients: Previously treated males aged 12–66 years with severe congenital hemophilia A (FVIII activity <1%) and at least 150 exposure days to any FVIII products.5

Study design: Multinational, open-label, non-randomized trial evaluating safety, pharmacokinetics, and clinical efficacy of Esperoct® when used for prophylaxis and treatment of bleeds. During the main phase, 175 patients received routine prophylaxis (50 IU/kg every 4 days), and 12 adults elected to be treated on-demand. A subset of patients (n=150) continued on in extension phase part 1; 139 continued into the non-randomized extension part 2, with 113 completing the trial.4,5

Co-primary endpoints: Incidence of FVIII inhibitors ≥0.6 BU (Bethesda units) and ABR (annualized bleeding rate) for patients on a prophylaxis regimen.4

Getting your patients started on Esperoct®.

Esperoct® package

Novo Nordisk is here to help your hemophilia A patients who want to make the switch to Esperoct®. Learn about our trial prescriptionh and product support programs.

See how we can help

Ready when they are.

Temperature stability icon

Esperoct® is the only extended half-life rFVIII that can be stored at up to 104˚F for up to 3 months or 86˚F for up to 12 months.1,7-9

See reconstitution steps

hPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance or who are uninsured, may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit program, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP and is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product. 

Study design

Giangrande et al (2017 and 2020)
pathfinder 2 phase 3 clinical trial: main phase and extension

Patients: Previously treated males aged 12–66 years with severe congenital hemophilia A (FVIII activity <1%) and at least 150 exposure days to any FVIII products.5

Study design: Multinational, open-label, non-randomized trial evaluating safety, pharmacokinetics, and clinical efficacy of Esperoct® when used for prophylaxis and treatment of bleeds. During the main phase, 175 patients received routine prophylaxis (50 IU/kg every 4 days), and 12 adults elected to be treated on-demand. A subset of patients (n=150) continued on in extension phase part 1; 139 continued into the non-randomized extension part 2, with 113 completing the trial.3,5

Co-primary endpoints: Incidence of FVIII inhibitors ≥0.6 BU (Bethesda units) and ABR (annualized bleeding rate) for patients on a prophylaxis regimen.5

Getting your patients started on Esperoct®.

Esperoct® package

Novo Nordisk is here to help your hemophilia A patients who want to make the switch to Esperoct®. Learn about our trial prescriptiong and product support programs.

See how we can help

Ready when they are.

Temperature stability icon

Esperoct® is the only extended half-life rFVIII that can be stored at up to 104˚F for up to 3 months or 86˚F for up to 12 months.4,6-8

See reconstitution steps

gPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance or who are uninsured, may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit program, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP and is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product. 

Selected Important Safety Information for Esperoct®

Contraindications

  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained

Adverse Reactions

  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions

Please click here for Esperoct® Prescribing Information.

References:

  1. Esperoct [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2019.
  2. Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013;11(4):670-678.
  3. Tiede A, Hampton K, Jiménez-Yuste V, Young G, Benchikh El Fegoun S, Chowdry P. Post-hoc analysis on the long-term response to fixed-dose prophylaxis with N8-GP in patients with haemophilia A. Haemophilia. 2021;10.1111/hae.14409.
  4. Giangrande P, Karim F, Nemes L, et al. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: final results from pathfinder2. J Thromb Haemost. 2020;18(1):5-14.
  5. Giangrande P, Andreeva T, Chowdary P, et al. Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A. Thromb Haemost. 2017;117(2):252-261.
  6. Data on file. Novo Nordisk Inc; Plainsboro, NJ.
  7. Eloctate® [package insert]. Cambridge, MA: Biogen Idec Inc.; 2020.
  8. Adynovate® [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2021.
  9. Jivi® [package insert]. Whippany, NJ: Bayer HealthCare LLC; 2018.

References:

  1. Data on file. Novo Nordisk Inc; Plainsboro, NJ.
  2. Tiede A, Hampton K, Jiménez-Yuste V, Young G, Benchikh El Fegoun S, Chowdry P. Post-hoc analysis on the long-term response to fixed-dose prophylaxis with N8-GP in patients with haemophilia A. Haemophilia. 2021;10.1111/hae.14409.
  3. Giangrande P, Karim F, Nemes L, et al. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: final results from pathfinder2. J Thromb Haemost. 2020;18(1):5-14.
  4. Esperoct [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2019.
  5. Giangrande P, Andreeva T, Chowdary P, et al. Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A. Thromb Haemost. 2017;117(2):252-261.
  6. Eloctate® [package insert]. Cambridge, MA: Biogen Idec Inc.; 2020.
  7. Adynovate® [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2021.
  8. Jivi® [package insert]. Whippany, NJ: Bayer HealthCare LLC; 2018.
Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support

Esperoct® is a registered trademark and novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2022 Novo Nordisk All rights reserved. US22ESP00061 November 2022

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials